{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"18.5","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive tivantinib 360 mg PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Tivantinib)"}],"paramType":"NUMBER","populationDescription":"Note: Study terminated for futility due to insufficient number of objective responders in first stage.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Objective Radiologic Response Rate (Complete or Partial Response) Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1","type":"PRIMARY","unitOfMeasure":"percentage of participants"}